Back to dashboard
All PlansCoverageHigh impact

Percutaneous Vertebroplasty, Kyphoplasty, Sacroplasty, and Coccygeoplasty

Regence BlueShield·Neurosurgery, Pain Management, Radiology +1 more·Medical Policy
Effective date
Oct 1, 2026
We identified it
Jul 7, 2026
Days to comply
86 days

Summary

New medical policy (SUR107) effective October 1, 2026, establishes coverage criteria for percutaneous vertebroplasty, kyphoplasty, sacroplasty, and coccygeoplasty. Coverage is limited to treatment of no more than three symptomatic vertebral fractures (T5-L5 spine) when conservative therapy fails and specific clinical criteria are met. Procedures on other spinal levels, for sacral/coccygeal insufficiency fractures, and using non-balloon mechanical devices are classified as investigational and non-covered.

Action Required

Before Oct 1, 2026
Before October 1, 2026: Billing and clinical teams must implement the following: (1) Update prior authorization protocols to require all seven documentation elements (imaging, pain correlation, functional impairment specifics, conservative therapy trial details, contraindication assessment, fracture location, and laterality) before claims are submitted. (2) Configure billing system to flag and deny claims for procedures on cervical spine, T1-T5 thoracic levels, sacrum, or coccyx as investigational/non-covered. (3) Establish internal verification process to confirm no more than three vertebral levels are treated per single date of service. (4) Create provider education materials emphasizing six-week minimum conservative therapy requirement (NSAIDs/analgesics, physical therapy, activity modification) with documented response before procedure authorization. (5) Update encounter templates to include specific instrumental ADL documentation fields (feeding, bathing, dressing, grooming, meal prep, household chores, occupational tasks) with description of functional limitation. (6) Modify prior auth denial templates to specify if claim is rejected for: investigational indication, inadequate conservative therapy documentation, exceeding three-level limit, contraindications present, or spinal level outside T5-L5. Failure to implement will result in claim denials and potential member billing liability.